title: [In vitro study of the antitumor immune responses induced by anti-idiotypic minibody vaccine of ovarian cancer].
abstract: OBJECTIVE
  To evaluate whether anti-tumor immune response can be induced in vitro with 6B11 anti-idiotypic minibody. and to explore its probability as ovarian cancer vaccine.
  
  
  METHODS
  Separated human peripheral blood mononuclear cells (PBMC) were stimulated and cultured by 6B11 minibody. The proliferations of PBMC and cytotoxin were observed by (3)HTdR and (51)Cr release test respectively. ELISA(Enzyme-Linked Immunosorbent Assay) test and Immune Flow Cytometry were used to analyze IFN-gamma in supernatant of the cultured cdlls and the change of T lymphocyte phenotype of PBMC with 6B11 minibody stimulated.
  
  
  RESULTS
  6B11 minibody could stimulate PBMC to proliferate, the best dose was 20 mg/L; it performed cytotoxin function to ovarian carcinoma cell line expressing OC166-9. IFN-gamma maintained at high level after stimulation. It stimulated proliferation of CD3(+) T cell and CD4(+) from PBMC after stimulation respectively. CD8(+) T cell proliferation was not clear. There was significant difference between stimulation and unstimulation in CD4(+)/CD8(+) ratio.
  
  
  CONCLUSIONS
  6B11 anti-idiotypic minibody can induce both humoral and cellular immunity against ovarian carcinoma in vitro. This paper has provided strong experimental evidence for clinical use of 6B11 minibody as anti-idiotype vaccines against ovarian carcinoma.
authors.affiliation: Gynecologic Oncology Center, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Xiao-hong
authors.initials: XH
authors.lastname: Chang
authors.forename: Heng
authors.initials: H
authors.lastname: Cui
authors.forename: Jie
authors.initials: J
authors.lastname: Feng
authors.forename: Wen-lan
authors.initials: WL
authors.lastname: Yang
authors.forename: Yi
authors.initials: Y
authors.lastname: Li
authors.forename: Tian-yun
authors.initials: TY
authors.lastname: Fu
authors.forename: Xue
authors.initials: X
authors.lastname: Ye
authors.forename: Hong-lan
authors.initials: HL
authors.lastname: Zhu
authors.forename: Hong-yan
authors.initials: HY
authors.lastname: Cheng
authors.forename: Ye-xia
authors.initials: YX
authors.lastname: Cheng
authors.forename: Hui-fang
authors.initials: HF
authors.lastname: Guo
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D019496:Cancer Vaccines / Q000276:immunology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002478:Cells, Cultured; D003603:Cytotoxins / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D006367:HeLa Cells; D006801:Humans; D007150:Immunohistochemistry; D007371:Interferon-gamma / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D003603:Cytotoxins; D011994:Recombinant Proteins; D007371:Interferon-gamma